Yangtze River Pharmaceutical Group was founded in 1971, is a combination of production, research, science, industry and trade integration of China's large pharmaceutical enterprise groups. Headquartered in Taizhou City, Jiangsu Province, which is located on the bank of Yangtze River and the famous city of "Yangtze River Delta", the Group has more than 5,000 employees, total assets of RMB 5 billion, and covers an area of about 2 million square meters. The group is centered on Yangzijiang Pharmaceutical Group Co., Ltd. and has the following subsidiaries: Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical Company Limited, Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Company Limited, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical Company Limited, Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical Company Limited, Yangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical Company Limited, and Yangzijiang Pharmaceutical Group Guangzhou Hai Rui Pharmaceutical Company Limited, Yangzijiang Pharmaceutical Group Jiangsu Hai Ci Biological Pharmaceutical Co. All the production plants and dosage forms of the group have passed the national GMP certification, and the group has a production base for extracting traditional Chinese medicines at the level of 10,000 tons per year.
Since its establishment, Yangzijiang Pharmaceutical has been aiming to become a bigger and stronger pharmaceutical industry and an internationalized enterprise, constantly accelerating the pace of scientific and technological innovation and independent brand construction, building up the core competitiveness of the enterprise, and rapidly improving the comprehensive economic strength of the enterprise. Since 1996, for 9 consecutive years, the comprehensive economic efficiency ranked first in Jiangsu pharmaceutical enterprises. 1997, for 8 consecutive years, among the top five of the country's more than 6,300 pharmaceutical enterprises. 2004, the group's sales revenue, profit and tax indexes jumped to the first place in the country's pharmaceutical enterprises, becoming China's pharmaceutical enterprises of the new subject of the scholar, and among the top 500 of China's largest groups and the top 500 taxpayers in the country.
In the enterprise development. Yangzijiang Pharmaceutical Group adheres to the development path of "science and technology" and "science and technology", and has formulated the new product development strategy of "three highs and one special", i.e., high-tech content, high value-added, high market capacity and unique therapeutic effect, High-tech content, high value-added, high market capacity and unique therapeutic effect. Every year, the company spends more than 100 million yuan on technological innovation and development. In addition to independent research and development, the company also cooperates with famous academicians, experts, and research institutes through industry-academia-research alliance, **** with the same development and research. Since 1996, the average annual development of more than 15 new drugs, of which about half of the self-developed. 2000, the group's technology center approved by the State Economic and Trade Commission of the Ministry of Science and Technology as a "national technology center". 2003, the National Development and Reform Commission, the Jiangsu Provincial Government invested and approved the establishment of the "Nanjing Hailings Chinese medicine". In 2003, the National Development and Reform Commission and Jiangsu Provincial Government invested in and approved the establishment of "Nanjing Hailing National Engineering Research Center for Pharmaceutical Process Technology of Traditional Chinese Medicine", which is dedicated to the modernization and internationalization of traditional Chinese medicine. In addition, the Group is also preparing to build scientific research centers in Beijing, Shanghai, Nanjing, Chengdu and other subsidiaries, shifting the tentacles of scientific research to big cities. At present, YPC has built several R&D platforms. The first is to build a chemical drug R&D technology platform with the national enterprise technology center at the Group's headquarters as the main body. The second is to build a modern Chinese medicine R&D technology platform with Nanjing Hailing National Engineering Research Center for Chinese Medicine Pharmaceutical Process Technology as the main body. Thirdly, we are building 4 new product R&D platforms of our subsidiaries with the new product departments of our subsidiaries in Shanghai and Beijing as the main body. Fourthly, we cooperate with high-level R&D personnel at home and abroad to ****build joint laboratories. For example, the Group's cooperative laboratory with Dr. Han Wei of Merck has been certified by four major U.S. pharmaceutical companies, led by Merck, and has successfully synthesized more than 1,000 brand-new compounds for efficacy screening. On the other hand, it is modifying 50-100 brand-new compounds that have been preliminarily verified to be effective for the treatment of diabetes and AIDS; and it has reached an agreement with Dr. Du of Stanford University on ****co-development of an innovative variety for the protection of cardiomyocytes, which has been initiated at present.
After more than 30 years of accumulation and innovation, Yangzijiang Pharmaceutical Group has now formed a product group of more than 10 series, more than 10 dosage forms, and more than 100 specifications in the fields of antibiotics, digestive drugs, circulatory drugs, antitumor drugs, antipyretic and analgesic drugs, etc., mainly based on traditional Chinese medicines, and Chinese and Western medicines, which cover the fields of antibiotics, digestive drugs, circulatory drugs, antitumor drugs, and antipyretic drugs. The company mainly produces tablets, capsules, granules, oral solution, syrup, ointment, lyophilized powder injection, large-volume injection, small-volume injection, and other 11 types of dosage forms, of which 5 products were approved by the National Development and Reform Commission as individually-priced, 7 products have been listed as "National Protected Varieties of Traditional Chinese Medicines", and 8 products have been awarded "Chinese Famous Brands". "More than 90 products are included in the medical insurance catalog, and more than 20 products are sold to the Middle East, Europe, Singapore, Slovakia, Indonesia, Hong Kong and other countries and regions. Blue Scutellaria Oral Liquid, Jingqianping Granules, Ou Su, Zuo Ke and other products are recognized by China Quality Certification Standards Association as "good products of trustworthy quality certified by national authoritative institutions", Wicker Bell Stomach Pain Punch is listed as "essential medicines for emergency treatment in Chinese medicine hospitals across the country", Jingqianping Granules are listed as "key products" by Chinese Medical Association, and more than 90 varieties are included in medical insurance catalog. Chinese Medical Association "key promotion project", the fist product "Gastric Su particles" won the authoritative newspapers, authoritative associations, authoritative website joint investigation of the "Chinese product quality and user satisfaction first brand
YPC Group focuses on creating a people-oriented corporate culture, and strives to build a harmonious enterprise. While vigorously developing its economy, YPC always adheres to the corporate philosophy of "Seek Progress, Protect All Beings", and fully supports the construction of the industry, health and education, poverty alleviation and disaster relief, and the construction of the army, etc., so as to return the society with its true feelings. The Group exclusively supports the "China Medical Science and Technology Award", the highest award for science and technology in China's medical and health industry, and subsidizes the "Wu Jieping Medical Foundation" and other academic foundations, as well as widely supports the Chinese Medical Association, the Chinese Academy of Traditional Chinese Medicine and the Chinese Academy of Medicine. The Group also extensively supports the academic activities of the Chinese Medical Association, the Chinese Society of Traditional Chinese Medicine, the Chinese Society of Hospital Management and the Chinese Medical Association. For three consecutive years since 2001, the Group has invested more than RMB 40 million yuan in the "Care for Western Health Action" with the support of the Ministry of Health, the State Council's Poverty Alleviation Office, the State Council's Committee for the Elderly, the All-China Women's Federation, and the State Administration of Radio, Film and Television, and has sent doctors, medicines, and medical supplies to more than 10 provinces, municipalities, and autonomous regions in the western region. "The Group sent doctors, medicines and knowledge to more than 10 provinces, cities and autonomous regions in the western region, covering a distance of more than 30,000 kilometers, which was warmly welcomed by the local people. The Group also subsidized hundreds of thousands of dollars for the organization of medical teams to perform free sight-restoring surgeries for elderly cataract patients living in poverty in the western region. In the fight against atypical pneumonia in 2003, Yangtzekiang donated medicines worth 5 million yuan to medical and healthcare institutions across the country and set up the "Yangtzekiang Anti-Africa Relief Fund", thus fulfilling the sense of social responsibility of an excellent pharmaceutical enterprise.
For the future, Yangzijiang Pharmaceutical Group is vigorously implementing its internationalization strategy. At present, as a major project in Jiangsu province along the river development "a valley six parks" leading park, Yangtzekiang Pharmaceutical Industrial Park covers an area of 570 acres, and will form an annual production capacity of 3 billion yuan after put into operation. By 2008, the Group will have built 6 production bases and 6 R&D centers, extending its production and scientific research to Beijing, Tianjin and Tangshan, the Pearl River Delta and the Yangtze River Delta. The Yangzijiang Pharmaceutical City has become the largest pharmaceutical industry cluster along the river economic zone in China. With the successful implementation of the Group's strategic deployment in Thailand, Ningxia, Shanghai, Sichuan, Beijing and Guangzhou, the pace of Yangzijiang's participation in the international market competition will be more solid. The advancing Yangtzekiang Pharmaceutical Group, like the incessant Yangtzekiang River, is dedicated to serving the health of all mankind with the sentiment of serving the country with industry.
Suzhong Pharmaceuticals
Suzhong Pharmaceuticals is a comprehensive manufacturer specializing in the production of pharmaceuticals with a history of 30 years. Over the years, it has continuously provided the market with more than one hundred varieties of excellent pharmaceutical products in both Chinese and Western pharmaceutical preparations. Because of its long history, Suzhong has been able to develop high-tech bio-engineering and genetically modified medicines more freely, and has created one after another high-tech medicines with exclusive patents, such as Wasabi, Yunzhi capsule, Shengxin, etc., which are well-known in the industry. Not only in the domestic, in the world in the field of counterparts, have been
experts and scholars of the high praise. At present, Suzhong has developed into one of the most comprehensive large-scale pharmaceutical factories in Greater China based on the concept of a structured pharmacological research base (Pharmaceutical City).
Suzhong Pharmaceutical's China headquarters is located in Jiangyan City, Jiangsu Province, China, with a factory area of over 300,000 square meters. The solid dosage form and liquid dosage form production plants are built in accordance with the most authoritative international standards for dosage form plants, and have been rigorously inspected and issued with GMP certificates of internationally recognized high quality production standards.
In the development of new drugs, Suzhong Pharmaceuticals has invested a huge amount of money every year, and set up a post-doctoral workstation with the highest honor. We have cooperated with advanced pharmaceutical companies in Europe and the United States to set up perfect pharmaceutical research centers to engage in a series of research and development in fermentation, synthesis, preparation and so on. As the traditional strain improvement technology has been quite mature, Suzhong has begun to build up technology in genetic engineering and bioconversion, and apply bioengineering conversion technology to develop intermediates of APIs, and is expected to create innovative achievements and status in biotechnology in the future.
Suzhong Pharmaceuticals employs more than 1,000 people in Greater China, with more than a quarter of them specialized in science and technology. The company's ability to develop its human resource pool has enabled Su Zhong to excel in the high-tech field of pharmaceuticals. We have begun to expand the most advanced fully-automated pharmaceutical production line in the world, and are actively regulating the passage of the U.S. FDA certification, in the hope that we can return to our customers with more advanced technology and more internationally competitive products.
Jiangsu Jichuan Pharmaceutical Group
Jichuan Pharmaceutical, located in the beautiful Yangtze River Delta, has a good location and three-dimensional transportation network. Its core business covers chemical base, modern Chinese medicine preparation, processing of traditional Chinese medicine tablets, pharmaceutical commercial wholesale, pharmaceutical raw materials, medical equipment and other industries, and gradually formed an area of 1,500 acres of "Jichuan Pharmaceutical Industrial Park".
Jichuan Pharmaceutical has a high level of pharmaceutical research and development system, a comprehensive national GMP certification of the manufacturing and quality inspection system, a combination of marketing network covering the whole country, thus laying the foundation for the core competitiveness of the pharmaceutical and health industry.
Jichuan Pharmaceuticals has six series of more than 150 specifications of state-approved drugs, including anti-infective, anesthesia, cerebrovascular, nutritional, sedative and detoxification, and digestive system, etc. The main products, Lyrica series and anti-ulcer drug JINUO, have been rated as "high-tech products of Jiangsu Province", and the Lidocaine Carbonate Injection has been classified as "National Torch Plan", and "National Torch Plan". Lidocaine Carbonate Injection was listed as "National Torch Plan Project", and is one of the professional pharmaceutical enterprises with the most varieties and dosage forms in pediatrics in China.
Jichuan Pharmaceutical, for four consecutive years among the top 100 pharmaceutical industry, has always followed the enterprise spirit of "with the boat ***, the sea and rivers", adhere to the "defense of health with science and technology," the business philosophy, efforts to enhance the brand image, create a good corporate culture, and continue to make the enterprise stronger. Corporate culture, and constantly make the enterprise stronger, bigger and longer.